Proteinuria modifies the effect of systolic blood pressure on total and cardiovascular disease mortality in patients with type 2 diabetes

被引:6
|
作者
Vepsalainen, T. [1 ]
Laakso, M. [2 ]
Kantola, I. [1 ]
Lehto, S. [2 ]
Juutilainen, A. [2 ]
Ronnemaa, T. [1 ]
机构
[1] Univ Turku, Dept Med, Turku Univ Hosp, FIN-20520 Turku, Finland
[2] Univ Eastern Finland, Kuopio Univ Hosp, Dept Med, Kuopio, Finland
关键词
cardiovascular disease; diabetes complications; proteinuria; systolic blood pressure; type; 2; diabetes; ATHEROSCLEROTIC VASCULAR-DISEASE; CORONARY-ARTERY-DISEASE; RISK-FACTORS; EUROPEAN GUIDELINES; KIDNEY-DISEASE; MELLITUS; MICROALBUMINURIA; HYPERTENSION; PREVENTION; OUTCOMES;
D O I
10.1111/j.1365-2796.2012.02581.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Hypertension and proteinuria are major risk factors for cardiovascular disease (CVD) mortality in patients with type 2 diabetes. Blood pressure (BP) targets have been progressively lowered in these patients to prevent or delay the progression of nephropathy. However, no long-term population-based studies have been reported on the interaction between BP and proteinuria with respect to total and CVD mortality in patients with type 2 diabetes. Design We prospectively followed 881 middle-aged type 2 diabetic patients, free of CVD events at baseline, for up to 18 years. Participants were categorized into four groups according to baseline systolic BP (<130, 130139, 140159 and =160 mmHg) and further stratified by proteinuria (=150 or >150 mg L-1). Cox proportional hazards model was used to estimate the joint association between systolic BP and proteinuria and the risk of mortality. Results During follow-up, 607 patients died including 395 because of CVD. After adjustment for confounding factors, total and CVD mortality were significantly higher in patients with proteinuria and systolic BP <130 mmHg compared with those with systolic BP between 130 and 160 mmHg. The prognosis was similar in patients with systolic BP <130 mmHg or =160 mmHg. Among patients without proteinuria, systolic BP <130 mmHg was associated with a nonsignificant reduction in mortality. Conclusions Type 2 diabetic patients with proteinuria and with systolic BP <130 mmHg may have an increased risk of CVD mortality. The presence of proteinuria should be taken into account when defining the target systolic BP level for the prevention of fatal CVD events in patients with type 2 diabetes.
引用
收藏
页码:611 / 619
页数:9
相关论文
共 50 条
  • [1] Proteinuria modifies the effects of physical activity on total and cardiovascular disease mortality rates in patients with type 2 diabetes
    Vepsalainen, T.
    Soinio, M.
    Lehto, S.
    Juutilainen, A.
    Laakso, M.
    Ronnemaa, T.
    DIABETOLOGIA, 2010, 53 (09) : 1886 - 1889
  • [2] Proteinuria modifies the effects of physical activity on total and cardiovascular disease mortality rates in patients with type 2 diabetes
    T. Vepsäläinen
    M. Soinio
    S. Lehto
    A. Juutilainen
    M. Laakso
    T. Rönnemaa
    Diabetologia, 2010, 53 : 1886 - 1889
  • [3] Cardiovascular disease modifies the relationship between systolic blood pressure and outcomes in people with diabetes
    Cai, Anping
    Wang, Jiabin
    Feng, Xiaoxuan
    Parati, Gianfranco
    Wang, Ji-Guang
    Feng, Yingqing
    Nie, Zhiqiang
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 218
  • [4] Proteinuria, macrovascular disease and blood pressure control in patients with type 2 diabetes
    Evans, AJ
    Krentz, AJ
    DIABETES, 2000, 49 : A370 - A370
  • [5] Blood Pressure Reduction With Dapagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
    Woo, Vincent
    Leiter, Lawrence A.
    Cefalu, William T.
    de Bruin, Tjerk W.
    Gause-Nilsson, Ingrid
    Parikh, Shamik J.
    Johnsson, Eva
    CIRCULATION, 2013, 128 (22)
  • [6] BLOOD PRESSURE AND THE RISK OF CARDIOVASCULAR DISEASE AMONG PATIENTS WITH TYPE 2 DIABETES
    Hu, G.
    CARDIOLOGY, 2014, 128 : 353 - 353
  • [7] Systolic blood pressure and cardiovascular events in type 2 diabetes: the lower the better
    Eryd, S. Adamsson
    Gudbjornsdottir, S.
    Manhem, K.
    Rosengren, A.
    Svensson, A. -M.
    Miftaraj, M.
    Franzen, S.
    Bjorck, S.
    DIABETOLOGIA, 2016, 59 : S502 - S503
  • [8] Blood pressure and mortality in patients with cardiovascular disease
    Chen, Jing
    Gu, Donfeng
    Whelton, P.
    Chen, Chung-Shiuan
    Wu, Xigui
    Duan, Xingfeng
    Reynolds, Kristi
    Hamm, L. Lee
    Whelton, Paul K.
    He, Jiang
    HYPERTENSION, 2006, 48 (04) : E41 - E41
  • [9] The combined effect of CRP and blood pressure on the risk of mortality in patients with type 2 diabetes
    Yan, Jia-min
    Zhang, Min-zhe
    Li, Qiang
    Lu, Gao-lei
    He, Qi-qiang
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [10] Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
    Fitchett, David
    Inzucchi, Silvio E.
    Lachin, John M.
    Wanner, Christoph
    van de Borne, Philippe
    Mattheus, Michaela
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    George, Jyothis T.
    Zinman, Bernard
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (03) : 364 - 367